Robertson D, Alvarez E, Steinman L, Hartung HP, Qian P, Selmaj K, Wray S, Wynn D, Fox EJ, Mok K, Miskin HP, Xu Y, Garner CA, Cree BAC. Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis. Front Immunol. 2026; 17:1771848.

Rosenberg JE, O'Donnell PH, Petrylak DP, Flaig TW, Hoimes CJ, Gupta S, Mar N, Friedlander TW, Tagawa ST, Bilen MA, Brown JR, McKay RR, Merchan JR, Srinivas S, Gorla S, Moreno BH, Davis G, Wirtz HS, Zhu Y, Milowsky MI. EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma. ESMO Open. 2026 Jun; 11(6):107700.

Acciani M, Zyla D, Niemeyer G, Harkins S, Parekh D, Pawlack E, Lacarbonara D, Kansara D, Ackerman ME, Niewiesk S, Porotto M, Hastie KM, Saphire EO. Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins. Cell Host Microbe. 2026 Jun 10; 34(6):1067-1081.e12.

Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ. VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines. Sci Transl Med. 2026 May 06; 18(848):eadr4509.

Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026 Apr 30; 82(4):564-574.

Panicker AJ, Hinman SS, Perreau J, Aslanpour A, Williams RL, Steinke S, Quinn E, Hernandez AL, Yandamuri SS, Irani SR, Longbrake EE, O'Connor KC. Generation of Monoclonal Autoantibodies From Myelin Oligodendrocyte Glycoprotein-Specific Human B Cells Using an Optofluidic-Based Platform. Neurol Neuroimmunol Neuroinflamm. 2026 May; 13(3):e200577.

Zyla DS, Della Marca R, Lacarbonara D, Niemeyer G, Zipursky G, Di Clemente L, Verbruggen MHL, van Dijk LLA, Ceh OM, Jonathan-Trakht G, Kalantarov G, Acciani M, Laterza G, Vyshenska D, Leedale C, Pawlack E, Hastie KM, Horvat B, de Swart RL, de Vries RD, Greninger AL, Niewiesk S, Ollmann Saphire E, Porotto M. Structural and mechanistic basis for antibody neutralization of the measles fusion protein. Nat Commun. 2026 Apr 06; 17(1).

Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, Bourlon MT, Taha T, Fukuokaya W, Myint ZW, Pichler R, Binz K, Molina-Cerrillo J, Kopecky J, de Liaño AG, Kucharz J, Fiala O, Matrana MR, Kopp RM, Di Civita MA, Zgura A, Ansari J, Kihnel R, De Felice F, Angel M, Monteiro FSM, Soares A, Urun Y, Buti S, Santini D, Santoni M. Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). Cancer Immunol Immunother. 2026 Mar 24; 75(4).

Dai Y, Brouillard J, Jaycox JR, Yeon SM, Huck JD, Yandamuri SS, Zhong Z, O'Connor KC, Burnina I, Henkel C, LeMay AK, Lilov A, McGurk E, Morrill M, Parker L, Sackett T, Sandberg C, Sivasubramanian A, Geoghegan JC, Ring AM. Off-target reactivity in clinical monoclonal antibodies. Structure. 2026 May 07; 34(5):747-757.e5.

Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.